<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04271293</url>
  </required_header>
  <id_info>
    <org_study_id>2897</org_study_id>
    <nct_id>NCT04271293</nct_id>
  </id_info>
  <brief_title>Oral Anti-coagulants in Fragile Patients With Percutaneous Endoscopic Gastrostomy and Atrial Fibrillation (ORIGAMI) Pilot Study</brief_title>
  <acronym>ORIGAMI</acronym>
  <official_title>anticOagulanti oRali in pazIenti fraGili Con gAstrostoMia endoscopIca Percutanea e fIbrillazione Atriale</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fondazione Policlinico Universitario Agostino Gemelli IRCCS</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fondazione Policlinico Universitario Agostino Gemelli IRCCS</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Compelling evidences support the safety of direct oral anticoagulants (DOAC) compared to&#xD;
      Vitamin K antagonists (VKA) in patients with non-valvular atrial fibrillation. The 2018&#xD;
      EHRA/ESC practical guide on the use of non-vitamin K antagonist oral anticoagulants stated&#xD;
      that &quot;data have shown that administration in a crushed form (e.g. via a nasogastric tube),&#xD;
      does not alter the bioavailability for apixaban, rivaroxaban, and edoxaban&quot;. However, at the&#xD;
      moment, there are no evidences supporting unequivocally the use of DOAC via PEG.&#xD;
&#xD;
      The purpose of this study is to evaluate the safety and efficacy of Edoxaban administered&#xD;
      through PEG in patients with an indication of anticoagulation according to the current&#xD;
      clinical practice.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Several studies support the safety of direct oral anticoagulants (DOAC) compared to Vitamin K&#xD;
      antagonists (VKA) in patients with non-valvular atrial fibrillation.&#xD;
&#xD;
      The 2018 EHRA/ESC practical guide on the use of non-vitamin K antagonist oral anticoagulants&#xD;
      affirmed that &quot;data have shown that administration in a crushed form (e.g. via a nasogastric&#xD;
      tube), does not alter the bioavailability for apixaban, rivaroxaban, and edoxaban&quot;. However,&#xD;
      at the moment, there are no evidences supporting unequivocally the use of DOAC via&#xD;
      Percutaneous endoscopic gastrostomy (PEG).&#xD;
&#xD;
      PEG is a method developed throughout the early 1980s for patients who need long-term enteral&#xD;
      nutrition due to neurodegenerative, neuromuscular and oncological diseases. This class of&#xD;
      patients is expected to increase significantly in the next decade.&#xD;
&#xD;
      Several studies have proven the safety of DOAC compared to VKA even recommending to prefer&#xD;
      DOAC over VKA wherever possible in the prevention of stroke and systemic embolism in adult&#xD;
      patients with non-valvular atrial fibrillation. However, there is no evidence to support&#xD;
      unequivocally the use of DOAC in patients fed PEG.&#xD;
&#xD;
      The purpose of this study is to evaluate the safety and efficacy of Edoxaban administered&#xD;
      through PEG in patients with an indication of anticoagulation according to the current&#xD;
      clinical practice.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 7, 2020</start_date>
  <completion_date type="Actual">August 10, 2021</completion_date>
  <primary_completion_date type="Actual">July 20, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Cardio-embolic events</measure>
    <time_frame>1 month</time_frame>
    <description>Description of the number of stroke, TIA and systemic embolism events symptomatic relapse of deep vein thrombosis/ pulmonary embolism in patients treated with Edoxaban via PEG.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Bleeding events</measure>
    <time_frame>1 month</time_frame>
    <description>any bleeding described according to the Bleeding Academic Research Consortium (BARC) scale.&#xD;
Type 0= No bleeding&#xD;
Type 1 = Bleeding that is not actionable and does not cause the patient to seek treatment.&#xD;
Type 2 = hemorrhage that &quot;is actionable&quot; and requires diagnostic studies, hospitalization, or treatment by a health care professional.&#xD;
Type 3a = bleeding plus hemoglobin drop of 3 to &lt; 5 g/dl; transfusion with overt bleeding.&#xD;
Type 3b = bleeding plus hemoglobin drop &lt; 5 g/dL; cardiac tamponade; bleeding requiring surgical intervention for control; bleeding requiring IV vasoactive agents.&#xD;
Type 3c = Confirmed Intracranial hemorrhage or intraocular bleed compromising vision&#xD;
Type 4 = CABG-related bleeding within 48 hours&#xD;
Type 5a = Probable fatal bleeding&#xD;
Type 5b = Definite fatal bleeding Type 0-2 will be conisdered minor bleedings. Type 3-5 will be considered major bleedings</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-factor Xa assay</measure>
    <time_frame>within 1 month</time_frame>
    <description>Description of the efficacy of the edoxaban by measuring th the anti-FXa activity.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">12</enrollment>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>Patients with PEG and oral anticoagulan treatment</arm_group_label>
    <description>Patients with PEG and indication for treatment with long-term oral anticoagulant therapy due to non valvular atrial fibrillation (FNAV), according to the current guidelines.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Edoxaban</intervention_name>
    <description>Edoxaban will be administered via PEG in patients who are eligible for the anticoagulant treatment according to the current guidelines.</description>
    <arm_group_label>Patients with PEG and oral anticoagulan treatment</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with Atrial Fibrillation. Patients with PEG and indication for treatment with&#xD;
        long-term oral anticoagulant therapy according to the guidelines.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with PEG and indication for treatment with long-term oral anticoagulant&#xD;
             therapy&#xD;
&#xD;
          -  Patients with Atrial Fibrillation&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Children under 18 years old.&#xD;
&#xD;
          -  Life expectancy &lt;30 days.&#xD;
&#xD;
          -  Lack of informed consent.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Domenico D'Amario</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fondazione Policlinico Gemelli IRCCS</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fondazione Policlinico Universitario Agostino Gemelli IRCCS</name>
      <address>
        <city>Rome</city>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Steffel J, Verhamme P, Potpara TS, Albaladejo P, Antz M, Desteghe L, Haeusler KG, Oldgren J, Reinecke H, Roldan-Schilling V, Rowell N, Sinnaeve P, Collins R, Camm AJ, Heidbüchel H; ESC Scientific Document Group. The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Eur Heart J. 2018 Apr 21;39(16):1330-1393. doi: 10.1093/eurheartj/ehy136.</citation>
    <PMID>29562325</PMID>
  </reference>
  <reference>
    <citation>Salmonson T, Dogné JM, Janssen H, Garcia Burgos J, Blake P. Non-vitamin-K oral anticoagulants and laboratory testing: now and in the future: Views from a workshop at the European Medicines Agency (EMA). Eur Heart J Cardiovasc Pharmacother. 2017 Jan;3(1):42-47. doi: 10.1093/ehjcvp/pvw032. Epub 2016 Dec 25. Review.</citation>
    <PMID>28025213</PMID>
  </reference>
  <reference>
    <citation>Tripodi A, Ageno W, Ciaccio M, Legnani C, Lippi G, Manotti C, Marcucci R, Moia M, Morelli B, Poli D, Steffan A, Testa S. Position Paper on laboratory testing for patients on direct oral anticoagulants. A Consensus Document from the SISET, FCSA, SIBioC and SIPMeL. Blood Transfus. 2018 Sep;16(5):462-470. doi: 10.2450/2017.0124-17. Epub 2017 Sep 13.</citation>
    <PMID>29106357</PMID>
  </reference>
  <reference>
    <citation>Galli M, D'Amario D, Andreotti F, Porto I, Vergallo R, Sabatelli M, Lancellotti S, Meleo E, De Cristofaro R, Crea F. Sustained safe and effective anticoagulation using Edoxaban via percutaneous endoscopic gastrostomy. ESC Heart Fail. 2019 Aug;6(4):884-888. doi: 10.1002/ehf2.12434. Epub 2019 Jun 11.</citation>
    <PMID>31184800</PMID>
  </reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>February 11, 2020</study_first_submitted>
  <study_first_submitted_qc>February 13, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 17, 2020</study_first_posted>
  <last_update_submitted>October 25, 2021</last_update_submitted>
  <last_update_submitted_qc>October 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fondazione Policlinico Universitario Agostino Gemelli IRCCS</investigator_affiliation>
    <investigator_full_name>DAMARIO DOMENICO</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Edoxaban</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

